Nuclear receptor PXR, transcriptional circuits and metabolic relevance

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 8, 2011, Pages 956-963

  Ihunnah, Chibueze A ^a   Jiang, Mengxi ^a   Xie, Wen ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Endobiotics; Gene regulation; Nuclear receptor; Xenobiotic receptor; Xenobiotics

Indexed keywords

BILE ACID; BILIRUBIN; CHOLESTEROL; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; GLUCAGON; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HERBACEOUS AGENT; INDINAVIR; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PREGNANE X RECEPTOR; RETINOIC ACID; RETINOID X RECEPTOR; RIFAMPICIN; RIFAXIMIN; ST JOHN WORT; STEROID; STEROID RECEPTOR COACTIVATOR 1; SULFOTRANSFERASE; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VITAMIN;

ANDROGEN METABOLISM; BILE ACID METABOLISM; BILIRUBIN METABOLISM; BONE METABOLISM; BONE MINERAL; CHROMATIN IMMUNOPRECIPITATION; DETOXIFICATION; DNA RESPONSIVE ELEMENT; DNA STRUCTURE; DRUG BIOAVAILABILITY; ENZYME REGULATION; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HUMAN; HYPERTENSION; LIPID METABOLISM; LIPOLYSIS; METABOLISM; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR GENE; REVIEW; SIDE EFFECT; STEROID METABOLISM; STEROID URINE LEVEL; TRANSCRIPTION REGULATION; VITAMIN METABOLISM; XENOBIOTIC METABOLISM;

HUMANS; RECEPTORS, STEROID; TRANSCRIPTION, GENETIC;

EID: 79958268830     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.01.014     Document Type: Review

References (151)

1. Kliewer S.A., et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998, 92(1):73-82.
2. Francis G.A., et al. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 2003, 65:261-311.
3. Jones S.A., et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 2000, 14(1):27-39.
4. Tolson A.H., Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv. Drug Deliv. Rev. 2010, 62(13):1238-1249.
5. Chirulli V., et al. CAR and PXR expression and inducibility of CYP2B and CYP3A activities in rat and rabbit lungs. Life Sci. 2005, 76(22):2535-2546.
6. Zollner G., et al. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 2006, 3(3):231-251.
7. Iyer M., Reschly E.J., Krasowski M.D. Functional evolution of the pregnane X receptor. Expert Opin. Drug Metab. Toxicol. 2006, 2(3):381-397.
8. Cho J.Y., et al. Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation. J. Lipid Res. 2009, 50(5):924-937.
9. Bhalla S., et al. Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism. J Biol Chem 2004, 279(43):45139-45147.
10. Bachmann K., et al. PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol. Res. 2004, 50(3):237-246.
11. Khogali A.M., et al. Hyperlipidaemia as a complication of rifampicin treatment. Tubercle 1974, 55(3):231-233.
12. Xie W., et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl Acad. Sci. USA 2001, 98(6):3375-3380.
13. Sugatani J., et al. Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol. Pharmacol. 2005, 67(3):845-855.
14. Staudinger J.L., et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl Acad. Sci. USA 2001, 98(6):3369-3374.
15. Geier A., et al. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim. Biophys. Acta 2007, 1773(3):283-308.
16. Matic M., et al. Pregnane X receptor: promiscuous regulator of detoxification pathways. Int. J. Biochem. Cell Biol. 2007, 39(3):478-483.
17. Kliewer S.A., et al. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog. Horm. Res. 1999, 54:345-367. discussion 367-8.
18. Lehmann J.M., et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 1998, 102(5):1016-1023.
19. Bertilsson G., et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl Acad. Sci. USA 1998, 95(21):12208-12213.
20. Blumberg B., et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev. 1998, 12(20):3195-3205.
21. Moore L.B., et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol. Endocrinol. 2002, 16(5):977-986.
22. Xie W., et al. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000, 406(6794):435-439.
23. Zhang H., et al. Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. Arch. Biochem. Biophys. 1999, 368(1):14-22.
24. Savas U., et al. Rabbit pregnane X receptor is activated by rifampicin. Drug Metab. Dispos. 2000, 28(5):529-537.
25. Handschin C., Podvinec M., Meyer U.A. CXR, a chicken xenobiotic-sensing orphan nuclear receptor, is related to both mammalian pregnane X receptor (PXR) and constitutive androstane receptor (CAR). Proc. Natl Acad. Sci. USA 2000, 97(20):10769-10774.
26. Chawla A., et al. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294(5548):1866-1870.
27. Klarlund J.K., et al. Signaling complexes of the FERM domain-containing protein GRSP1 bound to ARF exchange factor GRP1. J. Biol. Chem. 2001, 276(43):40065-40070.
28. Orans J., Teotico D.G., Redinbo M.R. The nuclear xenobiotic receptor pregnane X receptor: recent insights and new challenges. Mol. Endocrinol. 2005, 19(12):2891-2900.
29. Robinson-Rechavi M., Escriva Garcia H., Laudet V. The nuclear receptor superfamily. J. Cell Sci. 2003, 116(Pt 4):585-586.
30. Zhang B., Xie W., Krasowski M.D. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008, 9(11):1695-1709.
31. Squires E.J., Sueyoshi T., Negishi M. Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J. Biol. Chem. 2004, 279(47):49307-49314.
32. Li T., Chiang J.Y. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288(1):G74-G84.
33. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83(6):841-850.
34. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999, 20(3):321-344.
35. Umesono K., Evans R.M. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell 1989, 57(7):1139-1146.
36. Pollock C.B., Rogatcheva M.B., Schook L.B. Comparative genomics of xenobiotic metabolism: a porcine-human PXR gene comparison. Mamm. Genome 2007, 18(3):210-219.
37. Miki Y., et al. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol. Cell. Endocrinol. 2005, 231(1-2):75-85.
38. Lamba V., et al. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol. Appl. Pharmacol. 2004, 199(3):251-265.
39. Bauer B., et al. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol. Pharmacol. 2004, 66(3):413-419.
40. Lamba J., Lamba V., Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr. Drug Metab. 2005, 6(4):369-383.
41. Poulos T.L. Structural and functional diversity in heme monooxygenases. Drug Metab. Dispos. 2005, 33(1):10-18.
42. Poulos T.L. Cytochrome P450: molecular architecture, mechanism, and prospects for rational inhibitor design. Pharm. Res. 1988, 5(2):67-75.
43. Kishida T., et al. Strain differences in hepatic cytochrome P450 1A and 3A expression between Sprague-Dawley and Wistar rats. J. Toxicol. Sci. 2008, 33(4):447-457.
44. Drocourt L., et al. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab. Dispos. 2001, 29(10):1325-1331.
45. Ferguson S.S., et al. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol. Pharmacol. 2005, 68(3):747-757.
46. Mueller S.O., et al. Species-specific activation of nuclear receptors correlates with the response of liver drug metabolizing enzymes to EMD 392949 in vitro. Toxicol. Lett. 2010, 193(1):120-123.
47. Sonoda J., et al. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc. Natl Acad. Sci. USA 2002, 99(21):13801-13806.
48. Ma X., et al. Rifaximin is a gut-specific human pregnane X receptor activator. J. Pharmacol. Exp. Ther. 2007, 322(1):391-398.
49. Goodwin B., Hodgson E., Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 1999, 56(6):1329-1339.
50. Coumoul X., Diry M., Barouki R. PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem. Pharmacol. 2002, 64(10):1513-1519.
51. Wyde M.E., et al. The environmental pollutant 1, 1-dichloro-2, 2-bis (p-chlorophenyl)ethylene induces rat hepatic cytochrome P450 2B and 3A expression through the constitutive androstane receptor and pregnane X receptor. Mol. Pharmacol. 2003, 64(2):474-481.
52. Wyde M.E., et al. Di-n-butyl phthalate activates constitutive androstane receptor and pregnane X receptor and enhances the expression of steroid-metabolizing enzymes in the liver of rat fetuses. Toxicol. Sci. 2005, 86(2):281-290.
53. Chang T.K. Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J. 2009, 11(3):590-601.
54. Xu C., Li C.Y., Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28(3):249-268.
55. Wang H., LeCluyse E.L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 2003, 42(15):1331-1357.
56. Xie W., et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc. Natl Acad. Sci. USA 2003, 100(7):4150-4155.
57. Bock K.W. Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl-transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels. Biochem. Pharmacol. 2010.
58. Buckley D.B., Klaassen C.D. Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor alpha, and nuclear factor erythroid 2-related factor 2. Drug Metab. Dispos. 2009, 37(4):847-856.
59. Trottier J., et al. Coordinate regulation of hepatic bile acid oxidation and conjugation by nuclear receptors. Mol. Pharm. 2006, 3(3):212-222.
60. Gardner-Stephen D., et al. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab. Dispos. 2004, 32(3):340-347.
61. Borlak J., et al. N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism 2006, 55(6):711-721.
62. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum. Psychopharmacol. 2002, 17(5):233-238.
63. Bian H.S., et al. Induction of human sulfotransferase 1A3 (SULT1A3) by glucocorticoids. Life Sci. 2007, 81(25-26):1659-1667.
64. Alnouti Y., Klaassen C.D. Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice. J. Pharmacol. Exp. Ther. 2008, 324(2):612-621.
65. Duanmu Z., et al. Effects of dexamethasone on aryl (SULT1A1)- and hydroxysteroid (SULT2A1)-sulfotransferase gene expression in primary cultured human hepatocytes. Drug Metab. Dispos. 2002, 30(9):997-1004.
66. Fang H.L., et al. Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor. J. Pharmacol. Exp. Ther. 2007, 323(2):586-598.
67. Fang H.L., et al. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor. Mol. Pharmacol. 2005, 67(4):1257-1267.
68. Cui J.Y., et al. Genetic and epigenetic regulation and expression signatures of glutathione S-transferases in developing mouse liver. Toxicol. Sci. 2010, 116(1):32-43.
69. Knight T.R., Choudhuri S., Klaassen C.D. Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers. Toxicol. Sci. 2008, 106(2):329-338.
70. Naspinski C., et al. Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage. Toxicol. Sci. 2008, 104(1):67-73.
71. Mills J.B., et al. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J. Pharmacol. Exp. Ther. 2004, 309(1):303-309.
72. Schrenk D., et al. Up-regulation of transporters of the MRP family by drugs and toxins. Toxicol. Lett. 2001, 120(1-3):51-57.
73. Jigorel E., et al. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Dispos. 2006, 34(10):1756-1763.
74. Assem M., et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J. Biol. Chem. 2004, 279(21):22250-22257.
75. Hagenbuch B., Meier P.J. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004, 447(5):653-665.
76. Rae J.M., et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 2001, 299(3):849-857.
77. Kliewer S.A., Goodwin B., Willson T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 2002, 23(5):687-702.
78. Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin. Pharmacokinet. 2000, 38(6):493-504.
79. Moore L.B., et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(13):7500-7502.
80. Mai I., et al. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin. Pharmacol. Ther. 2004, 76(4):330-340.
81. Niemi M., et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 2003, 42(9):819-850.
82. Reimers D., Jezek A. The simultaneous use of rifampicin and other antitubercular agents with oral contraceptives. Prax Pneumol. 1971, 25(5):255-262.
83. Backman J.T., Olkkola K.T., Neuvonen P.J. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 1996, 59(1):7-13.
84. Polk R.E., et al. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob. Agents Chemother. 2001, 45(2):502-508.
85. Grub S., et al. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur. J. Clin. Pharmacol. 2001, 57(2):115-121.
86. Moore J.T., Kliewer S.A. Use of the nuclear receptor PXR to predict drug interactions. Toxicology 2000, 153(1-3):1-10.
87. Foster J.D., Nordlie R.C. The biochemistry and molecular biology of the glucose-6-phosphatase system. Exp. Biol. Med. (Maywood) 2002, 227(8):601-608.
88. Quinn P.G., Yeagley D. Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation. Curr Drug Targets Immune Endocr Metabol Disord 2005, 5(4):423-437.
89. Herzig S., et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001, 413(6852):179-183.
90. Kurukulasuriya R., et al. Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production. Curr. Med. Chem. 2003, 10(2):123-153.
91. Imai E., et al. Characterization of a complex glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 1990, 10(9):4712-4719.
92. Nakae J., et al. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J. Clin. Invest. 2001, 108(9):1359-1367.
93. Kodama S., et al. Human nuclear pregnane X receptor cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene. Biochem. J. 2007, 407(3):373-381.
94. Matsuzaki H., et al. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc. Natl Acad. Sci. USA 2003, 100(20):11285-11290.
95. Zhou J., et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 2006, 281(21):15013-15020.
96. Kodama S., et al. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol. Cell. Biol. 2004, 24(18):7931-7940.
97. Konno Y., Negishi M., Kodama S. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab. Pharmacokinet. 2008, 23(1):8-13.
98. Yoshikawa T., et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 2001, 21(9):2991-3000.
99. Misawa K., et al. Sterol regulatory element-binding protein-2 interacts with hepatocyte nuclear factor-4 to enhance sterol isomerase gene expression in hepatocytes. J. Biol. Chem. 2003, 278(38):36176-36182.
100. Kanayama T., et al. Interaction between sterol regulatory element-binding proteins and liver receptor homolog-1 reciprocally suppresses their transcriptional activities. J. Biol. Chem. 2007, 282(14):10290-10298.
101. Febbraio M., Silverstein R.L. CD36: implications in cardiovascular disease. Int. J. Biochem. Cell Biol. 2007, 39(11):2012-2030.
102. Koonen D.P., et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 2007, 56(12):2863-2871.
103. Zhou J., et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008, 134(2):556-567.
104. Hegardt F.G. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Biochem. J. 1999, 338(Pt 3):569-582.
105. Louet J.F., et al. Regulation of liver carnitine palmitoyltransferase I gene expression by hormones and fatty acids. Biochem. Soc. Trans. 2001, 29(Pt 2):310-316.
106. Wolfrum C., et al. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004, 432(7020):1027-1032.
107. Wolfrum C., et al. Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc. Natl Acad. Sci. USA 2003, 100(20):11624-11629.
108. Nakamura K., et al. Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J. Biol. Chem. 2007, 282(13):9768-9776.
109. Leonarduzzi G., Sottero B., Poli G. Oxidized products of cholesterol: dietary and metabolic origin, and proatherosclerotic effects (review). J. Nutr. Biochem. 2002, 13(12):700-710.
110. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 2003, 72:137-174.
111. Chiang J.Y. Regulation of bile acid synthesis. Front. Biosci. 1998, 3:d176-d193.
112. Li T., Chen W., Chiang J.Y. PXR induces CYP27A1 and regulates cholesterol metabolism in the intestine. J. Lipid Res. 2007, 48(2):373-384.
113. Masson D., et al. Expression of the pregnane X receptor in mice antagonizes the cholic acid-mediated changes in plasma lipoprotein profile. Arterioscler. Thromb. Vasc. Biol. 2005, 25(10):2164-2169.
114. Sporstol M., et al. Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem. Biophys. Res. Commun. 2005, 331(4):1533-1541.
115. Carr A., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12(7):F51-F58.
116. Eiris J.M., et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995, 45(6):1155-1157.
117. Zhai Y., et al. Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis. Mol. Endocrinol. 2007, 21(1):138-147.
118. Zawawi T.H., al-Hadramy M.S., Abdelwahab S.M. The effects of therapy with rifampicin and isoniazid on basic investigations for Cushing's syndrome. Ir. J. Med. Sci. 1996, 165(4):300-302.
119. Terzolo M., et al. Misdiagnosis of Cushing's syndrome in a patient receiving rifampicin therapy for tuberculosis. Horm. Metab. Res. 1995, 27(3):148-150.
120. Niwa T., et al. Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica 1998, 28(6):539-547.
121. Strott C.A. Sulfonation and molecular action. Endocr. Rev. 2002, 23(5):703-732.
122. Zhang B., et al. Pregnane X receptor as a therapeutic target to inhibit androgen activity. Endocrinology 2010, 151(12):5721-5729.
123. Fiorucci S., et al. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 2007, 13(7):298-309.
124. Hofmann A.F. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 1999, 159(22):2647-2658.
125. Kast H.R., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 2002, 277(4):2908-2915.
126. Frank C., et al. Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J. Mol. Biol. 2005, 346(2):505-519.
127. Jung D., Mangelsdorf D.J., Meyer U.A. Pregnane X receptor is a target of farnesoid X receptor. J. Biol. Chem. 2006, 281(28):19081-19091.
128. Tabb M.M., et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J. Biol. Chem. 2003, 278(45):43919-43927.
129. Ichikawa T., et al. Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J. Biol. Chem. 2006, 281(25):16927-16934.
130. Igarashi M., et al. Vitamin K induces osteoblast differentiation through pregnane X receptor-mediated transcriptional control of the Msx2 gene. Mol. Cell. Biol. 2007, 27(22):7947-7954.
131. Jones G., Strugnell S.A., DeLuca H.F. Current understanding of the molecular actions of vitamin D. Physiol. Rev. 1998, 78(4):1193-1231.
132. Pascussi J.M., et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest. 2005, 115(1):177-186.
133. Zhou C., et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J. Clin. Invest. 2006, 116(6):1703-1712.
134. Dent C.E., et al. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br. Med. J. 1970, 4(5727):69-72.
135. Shah S.C., et al. Rifampicin induced osteomalacia. Tubercle 1981, 62(3):207-209.
136. Birringer M., Drogan D., Brigelius-Flohe R. Tocopherols are metabolized in HepG2 cells by side chain omega-oxidation and consecutive beta-oxidation. Free Radic. Biol. Med. 2001, 31(2):226-232.
137. Swanson J.E., et al. Urinary excretion of 2, 7, 8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman is a major route of elimination of gamma-tocopherol in humans. J. Lipid Res. 1999, 40(4):665-671.
138. Stahl W., et al. Quantification of the alpha- and gamma-tocopherol metabolites 2,5,7,8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychroman and 2,7,8-trimethyl-2-(2'-carboxyethyl)-6-hydroxychroman in human serum. Anal. Biochem. 1999, 275(2):254-259.
139. Brigelius-Flohe R., Traber M.G. Vitamin E: function and metabolism. FASEB J. 1999, 13(10):1145-1155.
140. Kiyose C., et al. Alpha-tocopherol affects the urinary and biliary excretion of 2,7,8-trimethyl-2(2'-carboxyethyl)-6-hydroxychroman, gamma-tocopherol metabolite, in rats. Lipids 2001, 36(5):467-472.
141. Landes N., et al. Vitamin E activates gene expression via the pregnane X receptor. Biochem. Pharmacol. 2003, 65(2):269-273.
142. Brigelius-Flohe R. Vitamin E and drug metabolism. Biochem. Biophys. Res. Commun. 2003, 305(3):737-740.
143. Park D.J., et al. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J. Clin. Invest. 1999, 103(10):1399-1408.
144. Altucci L., et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 2001, 7(6):680-686.
145. Soprano D.R., Qin P., Soprano K.J. Retinoic acid receptors and cancers. Annu. Rev. Nutr. 2004, 24:201-221.
146. Wang T., et al. Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J. Pharmacol. Exp. Ther. 2008, 324(2):674-684.
147. Gu X., et al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J. Biol. Chem. 2006, 281(26):17882-17889.
148. Teng S., Piquette-Miller M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J. Pharmacol. Exp. Ther. 2005, 312(2):841-848.
149. Beigneux A.P., et al. Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response. Biochem. Biophys. Res. Commun. 2002, 293(1):145-149.
150. Zhou C., et al. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest. 2006, 116(8):2280-2289.
151. He P., et al. Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J. Clin. Pharmacol. 2006, 46(11):1356-1369.